PG 201

Drug Profile

PG 201

Alternative Names: Layla; PG201

Latest Information Update: 08 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroMed Co Ltd
  • Developer PMG Pharm Co Ltd
  • Class Antirheumatics; Phytotherapies
  • Mechanism of Action Cytokine modulators; Interleukin 1 beta inhibitors; Matrix metalloproteinase inhibitors; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 08 May 2014 PMG initiates enrolment in a phase IV LAYLA_P4_NB trial for Osteoarthritis in South Korea (NCT02049606)
  • 01 Sep 2013 PMG Pharm completes a phase IV LAYLA-P4 trial in Osteoarthritis (NCT01768468)
  • 01 Dec 2012 Launched for Osteoarthritis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top